Kybernin P

Antithrombin III, the active ingredient in Kybernin P, is an antithrombin concentrate presented as a sterile solution for injection for intravenous administration. It replaces deficient antithrombin in patients with hereditary antithrombin deficiency and helps prevent or treat thromboembolic complications in surgical or high‑risk settings.

GNH USA supplies Kybernin P as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide. The company ensures quality assurance, cold‑chain logistics and regulatory compliance for each shipment through rigorous testing and documentation.

Kybernin P, an antithrombin concentrate, acts on the coagulation cascade to restore antithrombin activity.

Hereditary antithrombin deficiency: restores antithrombin levels and reduces risk of spontaneous clotting. Prevention of thromboembolic events in surgical or high‑risk patients: provides prophylactic antithrombin activity to lower peri‑operative clot risk. Treatment of acute thrombotic episodes in antithrombin‑deficient patients: supports anticoagulation during active clot management.

Kybernin P may be associated with infusion‑related and systemic adverse reactions.

Common Side Effects: - Injection site reactions: erythema, pain, or swelling at the infusion site. - Transient fever: mild temperature elevation occurring shortly after administration. - Nausea: occasional feeling of queasiness without vomiting. - Headache: mild to moderate headache reported during treatment.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with respiratory distress, urticaria, or hypotension. - Thrombotic microangiopathy: rare syndrome characterized by thrombocytopenia and microvascular thrombosis. - Hemolysis: uncommon destruction of red blood cells leading to anemia.

Prior to using Kybernin P, clinicians should consider several safety and handling precautions. - Patient assessment: evaluate antithrombin levels and coagulation status before initiation. - Bleeding risk: monitor for signs of bleeding, especially in patients on concurrent anticoagulants. - Renal function: adjust monitoring in patients with impaired renal clearance. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Concomitant therapy: avoid simultaneous use with heparin products unless antithrombin levels are closely monitored. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kybernin P can interact with other agents that affect coagulation or antithrombin activity.

Major Interactions (Avoid): - Heparin: concurrent use may cause excessive anticoagulation due to enhanced heparin activity. - Direct thrombin inhibitors: combined effect may increase bleeding risk. - Antifibrinolytics: may counteract antithrombin’s anticoagulant effect.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR as antithrombin replacement can alter vitamin K antagonist response. - Aspirin or NSAIDs: increased risk of gastrointestinal bleeding; observe for signs of hemorrhage. - Oral contraceptives: potential additive effect on clotting; assess thrombotic risk.